v3.26.1
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Statement of Comprehensive Income [Abstract]      
Sales $ 386,013 $ 361,374 $ 470,170
Cost of sales 124,032 140,688 146,853
Gross profit 261,981 220,686 323,317
Selling, general and administrative expenses 332,979 420,922 598,250
Provision for credit losses 4,144 12,306 2,638
Research and development expenses 216,180 270,661 350,187
Loss on disposal and impairment of property, plant and equipment 137,235 30,279 108,722
Loss on impairment of intangible assets 49,922 0 0
Loss on impairment of goodwill 15,686 0 0
Government grants recognized in income (4,035) (7,947) (22,497)
Total operating expenses 752,111 726,221 1,037,300
Operating loss (490,130) (505,535) (713,983)
Interest and financing expenses (9,819) (5,637) (4,941)
Interest income 33,281 29,073 87,122
Share of losses from equity method investments (4,036) (2,700) (11,461)
Other income, net 208,602 527,636 558,776
(Loss) income before income taxes (262,102) 42,837 (84,487)
Income tax benefit (expense) 63,266 (2,181) (36,371)
Net (loss) income (198,836) 40,656 (120,858)
Less: net loss attributable to non-controlling interests (139,156) (50,249) (107,367)
Net (loss) income attributable to common shareholders of Sinovac $ (59,680) $ 90,905 $ (13,491)
Earnings (loss) per share      
Basic net (loss) income per share $ (0.83) $ 1.27 $ (0.19)
Diluted net (loss) income per share $ (0.83) $ 1.27 $ (0.19)
Weighted average number of shares of common stock outstanding      
– Basic 71,860,702 71,860,702 71,830,233
– Diluted 71,860,702 71,860,702 71,850,096
Net (loss) income $ (198,836) $ 40,656 $ (120,858)
Other comprehensive income (loss), net of tax of nil      
Foreign currency translation adjustments 273,972 (223,857) (277,710)
Unrealized gain (loss) on available-for-sale investments 6,729 (10,619) 8,779
Comprehensive income (loss) 81,865 (193,820) (389,789)
Less: comprehensive loss attributable to non-controlling interests (53,009) (140,337) (214,146)
Comprehensive income (loss) attributable to shareholders of Sinovac $ 134,874 $ (53,483) $ (175,643)